Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Combination of Metronomic Vinorelbine and Bevacizumab as 2nd Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

NCT00755170 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00755170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00755170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Combination of Metronomic Vinorelbine and Bevacizumab as 2nd Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
October 31, 2016
Enrollment
48 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer